Biogen (BIIB) EBT (2009 - 2026)

Biogen has reported EBT for 18 years, with the latest figure at $132.4 million in Q2 2026.

• On a quarterly basis, EBT fell 82.2% year-over-year to $132.4 million in Q2 2026; TTM through Jun 2026 was $1.0 billion, a 43.74% decrease from a year earlier, with the FY2025 full-year figure at $1.6 billion, down 18.34% from the prior year.
• EBT was $132.4 million for Q2 2026 at Biogen, down from $377.7 million in the prior quarter.
• The five-year high for EBT was $1.4 billion in Q3 2022, with the low at -$141.2 million in Q3 2023.
• Average EBT over 5 years is $492.3 million, with a median of $444.6 million recorded in 2023.
• The sharpest annual moves came in 2024 and 2025: EBT surged 419.41% in 2024, then plunged 119.21% in 2025.
• Over 5 years, EBT stood at $603.8 million in 2022, then tumbled by 51.71% to $291.6 million in 2023, then decreased by 0.03% to $291.5 million in 2024, then tumbled by 119.21% to -$56.0 million in 2025, then soared by 336.43% to $132.4 million in 2026.
• The last three EBT figures came in at $132.4 million (Q2 2026), $377.7 million (Q1 2026), and -$56.0 million (Q4 2025), per Business Quant data.